MEI Pharma gets a lift from positive initiation at Brean

|About: MEI Pharma, Inc. (MEIP)|By:, SA News Editor

Brean starts MEI Pharma (MEIP +5%) at Buy, citing "Pracinostat’s expected peak revenue of $700M in two indications, MDS and AML."

With several Phase 2 trials in the works, analyst Gene Mack sees "the commercial launch of Pracinostat in 2017/2018 contributing $12/share to valuation."

Price target is $16, representing upside of ~104% from Thursday's close.